https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Fri, 28 Jan 2022 09:23:19 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png https://mirror.vjregenmed.com 32 32 https://mirror.vjregenmed.com/video/99sk44ybubw-ct053-anti-gpc3-car-t-and-targeting-solid-tumors/ Wed, 10 Mar 2021 19:30:20 +0000 http://13.40.107.223/video/99sk44ybubw-ct053-anti-gpc3-car-t-and-targeting-solid-tumors/ Hong Ma, MD, MSc, MBA, CARsgen Therapeutics, Shanghai, China, provides an overview of recent data obtained from a number of Phase I clinical trials evaluating CT053, a fully human B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed/refractory (R/R) multiple myeloma. Studies discussed include LUMMICAR-1 (NCT03975907), LUMMICAR-2 (NCT03915184) and an investigator-initiated program in eastern China (NCT03716856, NCT03302403 and NCT03380039). In addition, Dr Ma describes recent and ongoing studies evaluating anti-GPC3 CAR-T cell therapy in patients with hepatocellular carcinoma. He also discusses overcoming the major challenges associated with targeting solid tumors using CAR-T therapies. This interview took place during the CAR-TCR Summit Europe 2021.

]]>